Summit Therapeutics (SMMT) Change in Account Payables (2019 - 2026)

Summit Therapeutics has reported Change in Account Payables for 8 years, with the latest figure at $6.8 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables rose 1810.67% year-over-year to $6.8 million; the trailing twelve-month figure through Mar 2026 stood at $21.7 million (up 1731.58% YoY), and the FY2025 full-year result was $15.3 million, up 659.45% from the prior year.
• Change in Account Payables for Q1 2026 stood at $6.8 million, up from -$2.1 million in the prior quarter.
• The five-year high for Change in Account Payables was $17.9 million in Q2 2025, with the low at -$3.5 million in Q2 2022.
• Historically, Change in Account Payables has averaged $1.3 million across 5 years, with a median of $297000.0 in 2023.
• Annual changes were most pronounced in 2024 — Change in Account Payables slumped 1122.56% — and 2026, when it surged 1810.67%.
• Summit Therapeutics' Change in Account Payables stood at -$2.4 million in 2022, then soared by 71.63% to -$672000.0 in 2023, then jumped by 327.53% to $1.5 million in 2024, then slumped by 240.29% to -$2.1 million in 2025, then soared by 417.11% to $6.8 million in 2026.
• The last three Change in Account Payables figures came in at $6.8 million (Q1 2026), -$2.1 million (Q4 2025), and -$839000.0 (Q3 2025), per Business Quant data.